苏州旺山旺水生物医药股份有限公司（旺山旺水-B，股票代码02630）于2026年7月15日公告，完成将100,220,667股境内非上市股份转换为H股。本次转换占此前已发行H股（不包括库藏股）约150.3074%。
经此次变动，旺山旺水-B在香港联交所上市的已发行H股由2026年6月30日的66,677,133股增至166,897,800股，境内非上市股份余700,000股。公司整体已发行股份达到167,597,800股。
公司表示，已就本次股份转换事宜获得适当授权，并严格遵守相关上市规则和相关法律法规的规定。公告由董事会秘书兼联席公司秘书郭婷签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.